EP. 1: Case 1: Non-Muscle Invasive, BCG-Refractory Bladder Cancer
Watch
EP. 2: Case 1: Treatments for NMIBC Refractory to BCG
EP. 3: Case 1: Impact of the BCG Shortage in Bladder Cancer
EP. 4: Case 1: Use of Blue Light Cystoscopy in Bladder Cancer
EP. 5: Case 1: Novel Agents in Superficial Bladder Cancer
EP. 6: Case 2: Cisplatin-Ineligible Metastatic Bladder Cancer
EP. 7: Case 2: Factors in Treating Cis-Ineligible Bladder Cancer
EP. 8: Case 2: Combination Therapy for Cis-Ineligible Bladder Cancer
EP. 9: Case 2: Exciting New Treatment for Cis-Ineligible Bladder Cancer
EP. 10: Case 2: I-O Therapy for Cisplatin-Ineligible Bladder Cancer
EP. 11: Case 3: Relapsed Muscle-Invasive Bladder Cancer, FGFR3+
EP. 12: Case 3: Treatment for FGFR3+ Bladder Cancer
EP. 13: Case 3: Molecular Testing in Bladder Cancer
EP. 14: Case 3: Mutational Patterns in Bladder Cancer
EP. 15: Case 3: FGFR-Targeted Therapy Adverse Events in Bladder Cancer
EP. 16: Case 3: Experience With FGFR-Targeted Therapies in Bladder Cancer
EP. 17: Case 4: MUC With Non-Muscle Invasive Recurrence
EP. 18: Case 4: Multiple Lines of Therapy in Recurrent Bladder Cancer
EP. 19: Case 4: Considering Special Populations in Bladder Cancer
EP. 20: Additional Insights: FGFRi-Associated Ocular AEs in Bladder Cancer
EP. 21: Additional Insights: Collaborative Approach to Bladder Cancer
EP. 22: Additional Insights: Experience with FGFR Inhibitors in Bladder Cancer
